Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance

BACKGROUND: We aimed to validate Decipher to predict adverse pathology (AP) at radical prostatectomy (RP) in men with National Comprehensive Cancer Network (NCCN) favorable-intermediate risk (F-IR) prostate cancer (PCa), and to better select F-IR candidates for active surveillance (AS). METHODS: In...

Descripción completa

Detalles Bibliográficos
Autores principales: Herlemann, Annika, Huang, Huei-Chung, Alam, Ridwan, Tosoian, Jeffery J., Kim, Hyung L., Klein, Eric A., Simko, Jeffry P., Chan, June M., Lane, Brian R., Davis, John W., Davicioni, Elai, Feng, Felix Y., McCue, Peter, Kim, Hyun, Den, Robert B., Bismar, Tarek A., Carroll, Peter R., Cooperberg, Matthew R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076042/
https://www.ncbi.nlm.nih.gov/pubmed/31455846
http://dx.doi.org/10.1038/s41391-019-0167-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076042/
https://www.ncbi.nlm.nih.gov/pubmed/31455846
http://dx.doi.org/10.1038/s41391-019-0167-9

Ejemplares similares